摘要
比较Semliki森林病毒(SFV)衍生的复制型DNA疫苗载体(复制型载体)和常规非复制型DNA疫苗载体(非复制型载体)的导入效率、表达效率、诱导凋亡率和免疫效果,从而评价其作为DNA疫苗载体的应用前景。使用等量SFV载体和常规DNA载体同等效率转染细胞后,复制型载体表达强度比非复制型载体高约3倍,其诱导凋亡的能力是非复制型载体的11倍;以不同剂量的SFV载体和常规DNA载体分别转染BHK21细胞,复制型载体各剂量组载体的表达量均高于非复制型载体。复制型载体在1μg组出现峰值,而非复制型载体则出现在4μg组。体内免疫的结果表明,SFV载体pSCA-SS1免疫的各组小鼠中,低剂量1μg组小鼠的总抗体滴度高于10μg和100μg剂量组;1μgpSCA-SS1免疫的小鼠产生的总抗体滴度与CTL水平,分别与pcDNA3-SS1免疫的小鼠中10μg和100μg组相当。但10μg、100μg组pSCA-SS1免疫小鼠的总抗体及CTL水平,都低于pcDNA3-SS1免疫的小鼠的10μg、100μg组。结果提示:SFV衍生的复制型DNA疫苗载体,在低剂量组时即可诱生与常规DNA疫苗载体高剂量组相近的免疫效果。
The purpose of this paper is to explore the applicative prospect of Semliki Forest virus(SFV)based replicative DNA vaccine by comparing its efficiency of transfection and expression,the rate of apoptosis and immune response with conventional nonreplicative DNA vaccineThe expression level of GFP and the rate of apoptosis of SFVbased DNA vector pSCAGFP were 3 times and 11 times as high as that of conventional DNA vector pGLGFP when transfecting cell with equal quantity,respectivelyThe expression level of the former was higher,with a peak on 1μg,than the latter with the peak on 4μg,at the same dosage in every group when using different transfection dosages.The total SS1 antibody titre of pSCASS1 induced at low dosage(1μg)was higher than the other two high dose groups(10μg & 100μg)The total antibody and CTL responses induced in mouse immuned with 1μg pSCA was equal to that immuned with 10μg and 100μg pcDNA3,respectivelyThe total antibody and CTL responses induced in mouse immuned with 10μg and 100μg of pSCASS1 was lower than that immuned with 10μg and 100μg of pcDNA3SS1The results suggest that SFVbased replicative DNA vaccine used in lower dosage is more efficient and safe than the conventional DNA vaccine
出处
《病毒学报》
CAS
CSCD
北大核心
2002年第4期325-331,共7页
Chinese Journal of Virology
基金
国家自然科学基金(No.39980026)
